MX2016000385A - Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad. - Google Patents
Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad.Info
- Publication number
- MX2016000385A MX2016000385A MX2016000385A MX2016000385A MX2016000385A MX 2016000385 A MX2016000385 A MX 2016000385A MX 2016000385 A MX2016000385 A MX 2016000385A MX 2016000385 A MX2016000385 A MX 2016000385A MX 2016000385 A MX2016000385 A MX 2016000385A
- Authority
- MX
- Mexico
- Prior art keywords
- vegf antagonist
- prematurity
- infant
- antagonist
- treating retinopathy
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 4
- 206010038933 Retinopathy of prematurity Diseases 0.000 title abstract 3
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003889 eye drop Substances 0.000 abstract 1
- 229940012356 eye drops Drugs 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 230000001839 systemic circulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F9/00821—Methods or devices for eye surgery using laser for coagulation
- A61F9/00823—Laser features or special beam parameters therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Otolaryngology (AREA)
- Optics & Photonics (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere al uso de un antagonista de VEGF en el tratamiento de trastornos neovasculares de la retina en infantes. En particular, la invención proporciona un método para tratar a un infante que tiene retinopatía de prematuro (ROP), en el que dicho método comprende la administración al ojo de un infante un antagonista de VEGF que, bien o no entra o se elimina rápidamente de la circulación sistémica. El término "infante" se suele utilizar para referirse a los niños desde el nacimiento hasta la edad de 12 meses. El antagonista de VEGF se puede administrar por vía intravítrea, por ejemplo, mediante inyección, o por vía tópica, por ejemplo, en forma de gotas para los ojos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845073P | 2013-07-11 | 2013-07-11 | |
| PCT/IB2014/063003 WO2015004626A2 (en) | 2013-07-11 | 2014-07-10 | Use of a vegf antagonist in treating retinopathy of prematurity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016000385A true MX2016000385A (es) | 2016-04-29 |
Family
ID=51211284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016000385A MX2016000385A (es) | 2013-07-11 | 2014-07-10 | Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20160159893A1 (es) |
| EP (1) | EP3019527A2 (es) |
| JP (1) | JP2016523956A (es) |
| KR (1) | KR20160030504A (es) |
| CN (1) | CN105377890A (es) |
| AR (1) | AR096893A1 (es) |
| AU (3) | AU2014288847A1 (es) |
| BR (1) | BR112016000282A2 (es) |
| CA (1) | CA2917813A1 (es) |
| HK (1) | HK1221231A1 (es) |
| MX (1) | MX2016000385A (es) |
| RU (1) | RU2676303C2 (es) |
| TW (1) | TW201536317A (es) |
| WO (1) | WO2015004626A2 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5166398B2 (ja) | 2006-04-07 | 2013-03-21 | エアーピオ セラピューティクス インコーポレイテッド | ヒトタンパク質チロシンホスファターゼβ（ＨＰＴＰβ）に結合する抗体及びその使用 |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| JP5536113B2 (ja) | 2009-07-06 | 2014-07-02 | アケビア セラピューティクス インコーポレイテッド | がん細胞の転移を予防するための化合物、組成物および方法 |
| EP3505182A1 (en) | 2011-10-13 | 2019-07-03 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| US9994560B2 (en) | 2014-03-14 | 2018-06-12 | Aerpio Therapeutics, Inc. | HPTP-β inhibitors |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| MY194736A (en) | 2015-09-23 | 2022-12-15 | Aerpio Therapeutics Inc | Methods of treating intraocular pressure with activators of tie-2 |
| CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
| EP3397271B1 (en) | 2015-12-30 | 2021-11-03 | Marshall University Research Corporation | Compositions and methods for treating retinopathy |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| WO2019169341A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| US11253502B2 (en) | 2019-04-29 | 2022-02-22 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the Schlemm's canal |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1539234A4 (en) * | 2002-09-05 | 2006-02-15 | Medimmune Inc | METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS |
| MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| CA2536912C (en) * | 2003-08-27 | 2015-03-31 | Eyetech Pharmaceuticals, Inc. | Combination therapy for the treatment of ocular neovascular disorders |
| WO2005110374A1 (en) | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| ES2971647T3 (es) * | 2005-04-15 | 2024-06-06 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| WO2007038453A2 (en) * | 2005-09-26 | 2007-04-05 | Advanced Ocular Systems Limited | Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation |
| US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| KR20170116221A (ko) * | 2007-11-07 | 2017-10-18 | 안트로제네시스 코포레이션 | 조산 합병증의 치료에 있어서의 제대혈의 용도 |
| CN102215875B (zh) * | 2008-10-16 | 2014-08-06 | 凯瑟琳·科根·法瑞纳斯 | 持续药物递送系统 |
| BRPI0921469B1 (pt) * | 2008-11-03 | 2022-01-18 | Molecular Partners Ag | Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica |
| JP2012525415A (ja) * | 2009-05-01 | 2012-10-22 | オプソテツク・コーポレイシヨン | 眼科疾患を処置または予防するための方法 |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| RU2469734C2 (ru) * | 2010-09-02 | 2012-12-20 | Григорий Владимирович Пантелеев | Лечебное средство для лечения расстройств аккомодаций "stiak" |
| US20140249191A1 (en) * | 2011-10-20 | 2014-09-04 | Avienne Pharmaceuticals Gmbh | Compositions for Controlling Vascularization in Ophthalmological and Dermatological Diseases |
| JP6336448B2 (ja) * | 2012-08-21 | 2018-06-06 | オプコ ファーマシューティカルズ、エルエルシー | リポソーム製剤 |
-
2014
- 2014-07-10 HK HK16109250.8A patent/HK1221231A1/zh unknown
- 2014-07-10 BR BR112016000282A patent/BR112016000282A2/pt not_active IP Right Cessation
- 2014-07-10 MX MX2016000385A patent/MX2016000385A/es unknown
- 2014-07-10 KR KR1020167000259A patent/KR20160030504A/ko not_active Ceased
- 2014-07-10 RU RU2016104398A patent/RU2676303C2/ru not_active IP Right Cessation
- 2014-07-10 JP JP2016524933A patent/JP2016523956A/ja active Pending
- 2014-07-10 EP EP14741408.0A patent/EP3019527A2/en not_active Withdrawn
- 2014-07-10 CN CN201480039605.XA patent/CN105377890A/zh active Pending
- 2014-07-10 US US14/903,435 patent/US20160159893A1/en not_active Abandoned
- 2014-07-10 TW TW103123847A patent/TW201536317A/zh unknown
- 2014-07-10 WO PCT/IB2014/063003 patent/WO2015004626A2/en not_active Ceased
- 2014-07-10 CA CA2917813A patent/CA2917813A1/en not_active Abandoned
- 2014-07-10 AU AU2014288847A patent/AU2014288847A1/en not_active Abandoned
- 2014-07-11 AR ARP140102578A patent/AR096893A1/es unknown
-
2017
- 2017-06-26 AU AU2017204326A patent/AU2017204326A1/en not_active Abandoned
-
2019
- 2019-07-16 AU AU2019206000A patent/AU2019206000A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160030504A (ko) | 2016-03-18 |
| AU2014288847A1 (en) | 2016-01-28 |
| RU2016104398A3 (es) | 2018-05-31 |
| JP2016523956A (ja) | 2016-08-12 |
| WO2015004626A3 (en) | 2015-05-28 |
| US20160159893A1 (en) | 2016-06-09 |
| CA2917813A1 (en) | 2015-01-15 |
| RU2016104398A (ru) | 2017-08-16 |
| CN105377890A (zh) | 2016-03-02 |
| AU2019206000A1 (en) | 2019-08-01 |
| AR096893A1 (es) | 2016-02-03 |
| RU2676303C2 (ru) | 2018-12-27 |
| TW201536317A (zh) | 2015-10-01 |
| BR112016000282A2 (pt) | 2017-12-12 |
| AU2017204326A1 (en) | 2017-07-13 |
| WO2015004626A2 (en) | 2015-01-15 |
| EP3019527A2 (en) | 2016-05-18 |
| HK1221231A1 (zh) | 2017-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016000385A (es) | Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad. | |
| MX2016000384A (es) | Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos. | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| PH12018501325A1 (en) | Compositions comprising human milk oligosaccharides for use in infants or young children to prevent or treat a health disorder by increasing glp-1 secretion | |
| BR112018069789A2 (pt) | medicamento obtido pela combinação do agonista de fxr e arb | |
| BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| PH12019500177A1 (en) | Treatment and prevention of sleep disorders | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| WO2014184576A3 (en) | Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain | |
| MX2018003028A (es) | Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc). | |
| SG10201903112WA (en) | Treatment of cancer using coenzyme q10 combination therapies | |
| BR112017024509A2 (pt) | tratamento de doença do cns com células de plexo coroide induzíveis encapsulada | |
| MX2017004658A (es) | Sulfatos de colesterol oxigenado para terapia contra trastornos provocados por al menos uno de actividad atenuada de leptina y un trastorno de almacenamiento lipidico. | |
| PH12017500098A1 (en) | Suspension compositions of cyclosporin a for subconjunctival and periocular injection | |
| EA201492102A1 (ru) | Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны | |
| WO2014144731A3 (en) | Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same | |
| Committee on Child Health Financing | Guiding principles for managed care arrangements for the health care of newborns, infants, children, adolescents, and young adults | |
| AR102494A1 (es) | Métodos para tratar enfermedades oculares | |
| Van Der Meer | Hyperammonaemic encephalopathy in a child: case report | |
| Kathirvel | Thrombocytopenia: case report | |
| 王扬 | How A Dog’s 9 Babies Came To Be Called | |
| Sedani | Hypersensitivity: case report | |
| Pratini | Baclofen/lorazepam | |
| Margetic | Bilateral leg oedema: case report |